Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8894870 | 0.80 | L3MBTL1 (0.50) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL10566182 | 0.80 | L3MBTL1 (0.50) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL10408346 | 0.77 | CA2 (0.51) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL122230 | 0.77 | SRC (0.58) | L3MBTL1SRCTDP1MEN1KMT2A | |
| Methylene Chloride SCHEMBL29220060 | 0.75 | SRC (0.52) | L3MBTL1SRCTDP1MEN1KMT2A | |
| SCHEMBL30161634 | 0.75 | L3MBTL1 (0.44) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL8519322 | 0.75 | TSHR (0.53) | L3MBTL1SRCTDP1MEN1KMT2A | |
| SCHEMBL8521617 | 0.75 | L3MBTL1 (0.49) | L3MBTL1SRCTDP1PKMMEN1 | |
| Water SCHEMBL7889250 | 0.75 | SRC (0.56) | L3MBTL1SRCTDP1PKMMEN1 | |
| SCHEMBL11433980 | 0.74 | SRC (0.50) | L3MBTL1SRCTDP1PKMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771688-B2 | Pyridine derivatives substituted by heterocyclic ring and amino group | AMPLYX PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210275510-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP | BASILEA PHARMACEUTICA INTERNATIONAL AG, ALLSCHWIL (CH) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275510-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND AMINO GROUP | ERG28, PDXK, PAH | L3MBTL1 4607/4885SRC 1451/4885TDP1 2944/4885 |
| US-11771688-B2 | Pyridine derivatives substituted by heterocyclic ring and amino group | ERG28, PDXK, PAH | L3MBTL1 4607/4885SRC 1451/4885TDP1 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.